Back to top
more

SCYNEXIS (SCYX)

(Delayed Data from NSDQ)

$1.47 USD

1.47
128,518

+0.03 (1.73%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $1.47 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SCYX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

SCYNEXIS, Inc. [SCYX]

Reports for Purchase

Showing records 1 - 20 ( 66 total )

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 1

10/24/2022

Company Report

Pages: 5

Cutting Bait on Brexafemme Launch, Focus on Development to Treat Hospital Fungal Infections; Rating Under Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 2

08/16/2022

Company Report

Pages: 7

2Q22: Looking for Brexafemme Re-Acceleration Coming Out of Summer Doldrums, and rVVC Approval November 30; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 3

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 4

05/13/2022

Company Report

Pages: 7

1Q22: Brexafemme Accleration Slow Coming; Lower Revs Plus Dilution Lower Our Target to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 5

03/31/2022

Company Report

Pages: 7

4Q21: Brexafemme Rx Acceleration Through 2022; rVVC Indication Approval by Year-End; Reiterate Buy, Lower PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 6

02/11/2022

Company Report

Pages: 5

Brexafemme Positive CANDLE Result Supports rVVC Label Expansion by Year-End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 7

11/15/2021

Company Report

Pages: 6

3Q21: Brexafemme Launched; Look to 2022 Sales Acceleration

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 8

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SCYX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 9

08/18/2021

Company Report

Pages: 6

2Q21: Brexafemme Rx Already Being Written As Boots Just Hit Ground; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 10

06/30/2021

Company Report

Pages: 7

Preparing for August Brexafemme VVC Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 11

06/03/2021

Company Report

Pages: 7

Brexafemme Gets 1st-Pass VVC Approval; 2H Launch Into Eager, Underserved Market; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 12

05/18/2021

Company Report

Pages: 7

1Q21: Brexafemme VVC June 1 PDUFA Date Imminent; Expect Approval 4Q First Sales; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 13

12/28/2020

Company Report

Pages: 8

Financing Provides Runway Into Launch; Expect June Ibrex VVC Approval; Reiterate Buy, But Lower PT to $20 on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 14

12/07/2020

Company Report

Pages: 7

Ibrex VVC Priority Review Confirmed with NDA Acceptance; June 1, 2021 PDUFA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 15

11/18/2020

Company Report

Pages: 9

3Q20: Ibrex VVC NDA Filed; See Relatively Low-Risk Approval Mid-21 Followed by CANDLE rVVC Phase 3 Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 16

10/15/2020

Company Report

Pages: 10

Ibrex VVC NDA Filed; Expect Priority Review and Mid-21 Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 17

08/24/2020

Company Report

Pages: 11

Taking a Fresh Look at VVC; Now See Majority of Opportunity as "On-Label" After Expected 2021 Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 18

05/19/2020

Company Report

Pages: 10

1Q20; Ibrex aVVC NDA Filing on Track for 2H; De-Risking Post Phase 3 Success Not Fairly Reflected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 19

04/22/2020

Company Report

Pages: 9

Ibrex Hits Stat Sig on All Endpoints in VANISH-306; ThatÂ’s Twofor-Two in aVVC; We See Mid-2021 Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 20

03/12/2020

Company Report

Pages: 7

4Q19 Results; Imminent Ibrex aVVC Phase 3 Data in April; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party